Compare OZ & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | ABOS |
|---|---|---|
| Founded | 2020 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 194.7M | 197.9M |
| IPO Year | 2020 | 2021 |
| Metric | OZ | ABOS |
|---|---|---|
| Price | $41.22 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $7.60 |
| AVG Volume (30 Days) | 15.0K | ★ 392.9K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,187,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 243.44 | N/A |
| 52 Week Low | $40.95 | $1.50 |
| 52 Week High | $69.00 | $3.60 |
| Indicator | OZ | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 14.04 | 33.71 |
| Support Level | N/A | $2.13 |
| Resistance Level | $48.00 | $2.42 |
| Average True Range (ATR) | 1.16 | 0.19 |
| MACD | -0.59 | -0.06 |
| Stochastic Oscillator | 0.99 | 1.82 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset. The majority of the revenue is earn from mixed-use segment.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.